Get the Stockscreener App
3.03
5.21%
0.15
After Hours:
2.97
-0.06
-1.98%
Q 32 Bio Inc stock is traded at $3.03, with a volume of 151.63K.
It is up +5.21% in the last 24 hours and up +32.89% over the past month.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.
See More
Previous Close:
$2.88
Open:
$2.83
24h Volume:
151.63K
Relative Volume:
0.05
Market Cap:
$37.28M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.72%
1M Performance:
+32.89%
6M Performance:
+89.97%
1Y Performance:
-3.19%
1-Day Range:
$2.825
$3.10
1-Week Range:
$2.72
$3.27
52-Week Range:
$1.345
$6.3699
Q 32 Bio Inc Stock (QTTB) Company Profile
Name
Q 32 Bio Inc
Sector
Industry
Phone
781-999-0232
Address
830 WINTER STREET, WALTHAM
Compare QTTB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QTTB
Q 32 Bio Inc
|
3.03 | 35.44M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Q 32 Bio Inc Stock (QTTB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-11-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-11-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | Raymond James | Strong Buy |
| Sep-11-24 | Initiated | Wells Fargo | Overweight |
| Jun-17-24 | Initiated | Guggenheim | Buy |
| May-21-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-22-22 | Reiterated | BTIG Research | Neutral |
| Feb-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-22-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-02-21 | Initiated | Stifel | Hold |
| Dec-14-20 | Resumed | H.C. Wainwright | Buy |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| Mar-16-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-24-20 | Initiated | Chardan Capital Markets | Buy |
| Nov-01-19 | Initiated | Oppenheimer | Perform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
View All
Q 32 Bio Inc Stock (QTTB) Latest News
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Aug Technicals: Can Q32 Bio Inc stock attract ESG capital inflowsQuarterly Profit Review & Verified Momentum Stock Ideas - moha.gov.vn
Q32 Bio Insiders Benefit From Selling Stock At US$2.86 - simplywall.st
Stock Market Recap: Why millennials buy Spire Inc LGR stockInsider Buying & Safe Swing Trade Setups - BỘ NỘI VỤ
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Q32 Bio Inc. (QTTB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Q32 Bio Inc. stock a defensive play in 2025Quarterly Profit Report & Accurate Technical Buy Alerts - Newser
Lee Kalowski, Q32 Bio CFO, sells $31k in shares By Investing.com - Investing.com UK
Is Q32 Bio Inc. stock recession proofWeekly Profit Report & Technical Analysis for Trade Confirmation - Newser
Q32 Bio CEO Morrison sells $77870 in stock By Investing.com - Investing.com South Africa
Insider Sell: Lee Kalowski Sells Shares of Q32 Bio Inc (QTTB) - GuruFocus
Lee Kalowski, Q32 Bio CFO, sells $31k in shares - Investing.com
CEO Morrison Sells 22,506 ($77.9K) Of Q32 Bio Inc [QTTB] - TradingView
Synopsys, Moderna, Strategy, Q32 Bio, Wolfspeed: Stocks Making The Biggest Moves Today - MSN
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M - MSN
Nothing is Better Than Q32 Bio Inc (QTTB) stock at the moment - Setenews
Block Trades: Will CGEN stock remain a Wall Street favorite2025 Technical Overview & Consistent Profit Alerts - BỘ NỘI VỤ
QTTB Stock Explodes Nearly 95%: Akebia Deal Transforms Q32 Bio’s Future - Bitget
Q32 Bio (QTTB) Stock Analysis Report | Financials & Insights - Benzinga
Will Q32 Bio Inc. stock attract ESG investorsTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Q32 Bio (QTTB) Stock Explodes After $592 Million Akebia Deal – Latest News, Analyst Targets and 2027 Outlook - ts2.tech
Q32 Bio Sells Complement Inhibitor ADX-097 - citybiz
Q32 sells rare kidney disease drug to Akebia for $12M up front - BioWorld MedTech
Q32 Bio Inc. (QTTB) Stock: Jumps on Akebia Acquisition of ADX-097 and Extended Runway - parameter.io
QTTB Stock Surges: Market Insight - StocksToTrade
Dow Dips 200 Points; Q32 Bio Shares Jump - inkl
Why Is Small-Cap Q32 Bio Stock Soaring On Monday? - inkl
Akebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal - marketscreener.com
Q32 Bio stock rockets after selling Phase 2 complement inhibitor to Akebia - Investing.com Nigeria
Q32 Bio sells complement inhibitor Adx-097 - marketscreener.com
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - TipRanks
Akebia Therapeutics (AKBA) Acquires Phase 2 Drug from Q32 Bio - GuruFocus
Q32 Bio sells complement inhibitor ADX-097 to Akebia - TipRanks
Q32 Bio Sells ADX-097 to Akebia Therapeutics - TipRanks
Akebia Announces Establishment of Rare Kidney Disease Pipeline - The Manila Times
EBIT per share of Q32 Bio Inc – LSE:0T6G - TradingView
Cash per share of Q32 Bio Inc – LSE:0T6G - TradingView
Q32 Bio Inc.Common Stock (Nasdaq:QTTB) Stock Quote - Markets Financial Content
Form 8-KCurrent report - ADVFN
Layoff Tracker: Novartis Cuts 550 Employees as Swiss Manufacturing Priorities Shift - BioSpace
Q32 Bio Inc. Faces Financial Challenges Amid Development Efforts - MSN
Q 32 Bio Inc Stock (QTTB) Financials Data
There is no financial data for Q 32 Bio Inc (QTTB). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):